3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Ovarian Neoplasms
3
Brain Neoplasms
3
Stomach Neoplasms
2
Pain, Postoperative
2
Pain
2
Neoplasms
2
Fallopian Tube Neoplasms
2
Breast Neoplasms
2
Warts
1
Stroke
1
Sepsis
1
Schwannomatosis
1
Prostatic Neoplasms
1
Pleural Effusion
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Pancreatic Cyst
1
Neuroinflammatory Diseases
1
Neurilemmoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hypoxia
1
Hyperthermia
1
Hemorrhage
1
Glycopyrrolate
1
Interventions
Cisplatin
14
Paclitaxel
12
pembrolizumab
9
Fluorouracil
7
Radiotherapy
6
Irinotecan
5
Esophagectomy
5
tislelizumab
4
Oxaliplatin
4
Leucovorin
4
Drug Therapy
4
Carboplatin
4
toripalimab
3
Levoleucovorin
3
Docetaxel
3
Capecitabine
3
camrelizumab
2
Taxes
2
Radiation
2
Nivolumab
2
Injections
2
130-nm albumin-bound paclitaxel
2
spartalizumab
1
sintilimab
1
palbociclib
1
nimotuzumab
1
nazartinib
1
lenvatinib
1
ivarmacitinib
1
futibatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
Saline Solution
×
90 days
×
Clear all
NCT04210115
2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
703 enrolled